Compliance Rate
Compliance Rate
48.0%
Compliant submissions
48
Incompliant submissions
52
Total trials
100
Your Clinical Trials
Showing 540800 of 542236 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/15/21
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 07/31/16
End: 09/30/19
Due: 09/30/20
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 11/30/15
Due: 11/30/16
Phase: N/A
Priority: Normal
Start: 12/10/15
End: 12/17/15
Due: 12/17/16
Phase: N/A
Priority: Normal
Start: 12/31/08
End: 12/31/09
Due: 12/31/10
Phase: N/A
Priority: Normal
Start: 03/01/23
End: 06/30/24
Due: 06/30/25
How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 09/30/12
Due: 09/30/13
Phase: N/A
Priority: Normal
Start: 05/15/20
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 08/03/17
End: 12/21/17
Due: 12/21/18
Phase: N/A
Priority: Normal
Start: 02/29/16
End: 12/30/21
Due: 12/30/22
Phase: N/A
Priority: Normal
Start: 10/31/09
End: 04/30/11
Due: 04/30/12
Phase: N/A
Priority: Normal
Start: 07/08/22
End: 07/08/24
Due: 07/08/25
Phase: N/A
Priority: Normal
Start: 04/04/16
End: 06/30/16
Due: 06/30/17
Phase: N/A
Priority: Normal
Start: 02/14/23
End: 01/31/24
Due: 01/31/25
Phase: N/A
Priority: Normal
Start: 03/31/10
End: 06/30/12
Due: 06/30/13
Phase: N/A
Priority: Normal
Start: 08/31/22
End: 09/30/23
Due: 09/30/24
Phase: N/A
Priority: Normal
Start: 09/01/12
End: 02/06/18
Due: 02/06/19
Phase: N/A
Priority: Normal
Start: 03/28/22
End: 08/08/26
Due: 08/08/27
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 10/31/25
Due: 10/31/26
Phase: N/A
Priority: Normal
Start: 05/05/26
End: 07/15/26
Due: 07/15/27
Phase: N/A
Priority: Normal
Start: 05/01/25
End: 01/22/26
Due: 01/22/27
Phase: N/A
Priority: Normal
Start: 07/01/25
End: 01/01/26
Due: 01/01/27
Phase: N/A
Priority: Normal
Start: 08/01/25
End: 03/31/28
Due: 03/31/29
Phase: N/A
Priority: Normal
Start: 11/27/17
End: 01/25/23
Due: 01/25/24
Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection
Phase: N/A
Priority: Normal
Start: 04/29/19
End: 11/27/19
Due: 11/27/20